Abstract:This study aimed to compare the efficacy and safety of generic exenatide with branded exenatide Byetta® in Chinese patients with type 2 diabetes mellitus (T2DM) inadequately controlled on monotherapy or combination therapy of metformin and insulin secretagogues. A multicenter, randomized, controlled, non-inferiority trial was performed. A total of 240 patients with T2DM and glycated hemoglobin (HbA1c) ≥ 7% (53 mmol/mol) to ≤ 9.0% (75 mmol/mol) on monotherapy or combination therapy of metformin and insulin secretagogues for at least 3 months were randomized into generic exenatide or branded exenatide groups with a 1:1 ratio for 16 weeks of treatment. The primary endpoint was the change in HbA1c levels from baseline at week 16, with a non-inferiority margin of − 0.35% (− 3.83 mmol/mol) (lower bound of one-sided 95% confidence interval (CI) > − 0.35% (− 3.83 mmol/mol)). Secondary endpoints included the proportion of participants achieving HbA1c < 7% (53 mmol/mol), the changes in fasting plasma glucose (FPG), 2-h postprandial glucose (2hPG) following a standard meal, 7-point self-monitoring blood glucose (SMBG) profiles, body weight change from baseline at week 16 and the change in HbA1c levels from baseline at week 8. Safety issues were also evaluated. After 16 weeks of treatment, HbA1c levels decreased significantly from baseline in the two groups, with a reduction of − 1.10% ± 1.31% (− 12.0 mmol/mol ± 14.3 mmol/mol) in the generic exenatide group and − 1.08% ± 1.11% (− 11.8 mmol/mol ± 12.1 mmol/mol) in the branded exenatide group (both P < 0.001). The least-squares mean difference of HbA1c reduction between the two groups was − 0.03% (− 0.33 mmol/mol), with a lower one-sided 95% CI limit of − 0.27% (− 2.95 mmol/mol), which was higher than the prespecified non-inferiority margin of − 0.35% (− 3.83 mmol/mol). Moreover, there were no significant differences in the proportion of participants achieving HbA1c < 7% (53 mmol/mol) and the changes in FPG, 2hPG, 7-point SMBG profiles and body weight at week 16 and the change in HbA1c levels from baseline at week 8 (all P > 0.05) between the two groups. The incidence of adverse events, including the incidence of hypoglycemia (18.3% and 17.5%, respectively), was similar for the generic and branded exenatide groups (P > 0.05). In patients with T2DM inadequately controlled on monotherapy or combination therapy of metformin and insulin secretagogues, add-on treatment with generic exenatide demonstrated non-inferiority to branded exenatide in terms of improvements in HbA1c after 16 weeks of treatment. Furthermore, the two drugs were also similar for other efficacy endpoints and safety profile. Trial registration Chinese Clinical Trial Registry: ChiCTR-IPR-15006558, Date registered May 27, 2015.

Exenatide Twice Daily Plus Glargine Versus Aspart 70/30 Twice Daily in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Premixed Human Insulin and Metformin

Cost-Effectiveness Analysis of Exenatide Twice Daily (BID) Versus Insulin Glargine Once Daily (QD) As Add-on Therapy in Chinese Patients with Type 2 Diabetes Mellitus Inadequately Controlled by Oral Therapies.

Cost-Effectiveness of Exenatide Twice Daily vs. Insulin Glargine as Add-on Therapy to Oral Antidiabetic Agents in Type 2 Diabetes in China

Comparing the Effects of Twice-Daily Exenatide and Insulin on Renal Function in Patients with Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Controlled Trial.

Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled, parallel-group study.

Efficacy and Safety of Additional Basal Insulin or Oral Antidiabetic Drug in Type 2 Diabetes Poorly Controlled with One Oral Antidiabetic Drug

The Value of Short- and Long-Acting Glucagon-Like Peptide-1 Agonists in the Management of Type 2 Diabetes Mellitus: Experience with Exenatide

Efficacy of Exenatide Administered Twice Daily in Body Mass Index Reduction in Patients with Type 2 Diabetes Mellitus

Switching from Glargine+insulin Aspart to Glargine+insulin Aspart 30 Before Breakfast Combined with Exercise after Dinner and Dividing Meals for the Treatment of Type 2 Diabetes Patients with Poor Glucose Control – a Prospective Cohort Study

[Post-Hoc Analyses of Type 2 Diabetes Patients Switch from Premixed Insulin Regimen to Basal Insulin Plus Oral Hypoglycemic Agents Regimen].

Effects of Exenatide Versus Insulin Glargine on Body Composition in Overweight and Obese T2DM Patients: a Randomized Controlled Trial

Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients with Newly Diagnosed Type 2 Diabetes

Exenatide Once-Weekly Injection for the Treatment of Type 2 Diabetes in Chinese Patients: Current Perspectives

Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance.

Clinical study of treatment switching from premixed insulin to basal insulin combined with oral hypoglycemic drugs in patients with type 2 diabetes

Glargine insulin/gliclazide MR combination therapy is more effective than premixed insulin monotherapy in Chinese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs.

Evaluation of the Curative Effect of Exenatide and Insulin Detemir on the Treatment of Type 2 Diabetes by Continuous Glucose Monitoring System

Efficacy and Safety of Exenatide in Patients of Asian Descent with Type 2 Diabetes Inadequately Controlled with Metformin or Metformin and a Sulphonylurea

A Prospective Study to Optimize Insulin Treatment by Switching to Insulin Glargine in Type 2 Diabetic Patients Previously Uncontrolled on Premixed Insulin: the Optimization Study

Efficacy and safety of exenatide in Chinese patients with type 2 diabetes inadequately controlled with metformin or metformin and a sulfonylurea

Efficacy and Safety of Generic Exenatide Injection in Chinese Patients with Type 2 Diabetes: a Multicenter, Randomized, Controlled, Non-Inferiority Trial.